echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials

    China National Institute of Biological Sciences of Sinopharm Group's recombinant new coronavirus vaccine approved for clinical trials

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 9, 2021, the recombinant new coronavirus vaccine of the China National Institute of Biological Research of Sinopharm Group obtained the clinical trial approval from the National Medical Products Administration.
    This is the new crown vaccine of another technical route after the two new inactivated vaccines of Sinopharm Sinopharm, and it has become China's third new crown vaccine.

    The recombinant new coronavirus vaccine is based on the natural structural characteristics of the new coronavirus spike protein (S protein) receptor binding region (RBD), and uses structural biology and computational biology to independently design and develop, and uses genetic engineering technology to construct engineered cell lines and recombinant expression Antigen protein, clear target, strong pertinence.
    After immunization, it can induce the body to produce targeted neutralizing antibodies, thereby blocking the combination of the virus and the recipient cells and exerting a protective effect.

    China Biotech stated that the genetic recombinant protein vaccine has a mature technology route and is suitable for large-scale production.
    Live viruses and other infectious materials are not involved in the whole preparation process, and it does not need to be carried out in a high-grade biosafety environment.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.